Trial register facet
Phase 3 trial records
351 records at phase 3.
Showing 0 records on this page
Records
351 documents · page 1 of 15
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STRIDE | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 792 | 2025 | Moderate |
| ESSENCE | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,197 | 2025 | Moderate |
| SOUL | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,650 | 2025 | Moderate |
| SURMOUNT-5 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 751 | 2025 | High |
| SURMOUNT-KOA | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Low |
| SURPASS-CVOT | Tirzepatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 13,299 | 2025 | Moderate |
| ATTAIN-1 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Moderate |
| ATTAIN-2 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| ACHIEVE-1 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| ACHIEVE-2 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, active-controlled | — | 2025 | Not rated |
| REDEFINE-1 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 3,417 | 2025 | Moderate |
| REDEFINE-2 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,206 | 2025 | Moderate |
| GLORY-1 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 610 | 2025 | Moderate |
| ECNO-PH3-CN-OBESITY | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 664 | 2025 | Low |
| ECNO-PH3-CN-T2D | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| EXENATIDE-GE-PD | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 194 | 2025 | Moderate |
| SURMOUNT-KOA-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ATTAIN-1-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ATTAIN-2-ELDERLYprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-1-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-ELDERLYprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-1-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-2-OLEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| STRIDE-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
page 1 of 15